Johnite.net

...home of the St. Johns Medical College Community

  • Increase font size
  • Default font size
  • Decrease font size
Home

The International Atomic Energy Agency collaborating with Saint Johns Research Institute

E-mail Print PDF

Building Partnerships for a Lifetime

IAEA Collaborating Centre in Nutrition Inaugurated in India

26 May 2010
 This week the IAEA formalises its relationship with the St. John´s Research Institute (SJRI) in Bangalore, India, designating it one of the IAEA´s select collaborating centres worldwide.

The SJRI has been working with the IAEA´s Nutrition and Health-Related Environmental Studies Section since 1988, and is well networked in India as well as internationally.

A technician loads processed blood samples into a Thermal Ionization Mass Spectrometer for measuring iron absorption at the St. John´s Research Institute in Bangalore, India

"The SJRI is not only special because of its excellent track record, but because it´s the first institution we have chosen to be a collaborating centre in nutrition," says Lena Davidsson, Head of the IAEA´s Nutritional and Health-related Environmental Studies Section.

The Institute´s research focuses on nutrition, cancer, as well as infectious and lifestyle-related diseases.

"This is an exceptionally good example of a centre where stable isotope technique is being used for nutrition-related research in a developing country," says Davidsson.

The longstanding relationship between the IAEA and the SJRI has provided a number of benefits to both parties. For example, the SJRI analyses samples for Asian and African Member States, provides lecturers for the Agency´s courses on stable isotope technique, and trains research fellows from Member States worldwide.

Background

The IAEA has introduced the concept of collaborating centres to assist in implementing specific areas of its programme of research, development and training in nuclear technologies, while capitalizing upon and helping to expand the capabilities of Member States´ scientific and technical institutions.

Designation as a centre does not imply preeminence in the specific scientific field; rather it is a public recognition of the collaboration with the IAEA in a specific field of work.

See Story Resources for more information.

-- By Sasha Henriques, IAEA Division of Public Information

http://www.iaea.org/NewsCenter/News/2010/buildingrelations.html

 

Poster Presentation ASCO 2010 Chicago Meeting

E-mail Print PDF

Phase I trial of oxaliplatin and doxorubicin in children and adolescents with recurrent solid tumors.


Sub-category: Pediatric Solid Tumors

Category: Pediatric Oncology

Meeting: 2010 ASCO Annual Meeting


Citation: J Clin Oncol 28:7s, 2010 (suppl; abstr 9543)

Abstract No: 9543

 
Attend this session at the ASCO Annual Meeting!

Session: Pediatric Oncology

Type: General Poster Session

Time: Sunday June 6, 2:00 PM to 6:00 PM

Location: S Hall A2

!

 

Author(s): L. Mascarenhas, S. Armenian, J. L. Harrington, H. Mahmoud, R. Sposto, M. H. Malogolowkin; Childrens Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA; City of Hope, Duarte, CA; Children's Hospital Los Angeles, Los Angeles, CA

Abstract:

Background: The combination of a platinum agent and anthracycline has activity in pediatric solid tumors. This trial evaluated the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of oxaliplatin combined with doxorubicin given with dexrazoxane intravenously in pediatric patients with recurrent solid tumors and evaluated the pharmacokinetics (PK) of oxaliplatin when administered with doxorubicin.

 Methods: Patients with prior exposure to anthracyclines were eligible. Oxaliplatin was administered on day 1 and Doxorubicin on days 1-3 of each 21-day course. Three dose levels were evaluated: 1) oxaliplatin 105 mg/m2 and doxorubicin 20 mg/m2, 2) oxaliplatin 130 mg/m2 and doxorubicin 20 mg/m2 and 3) oxaliplatin 130 mg/m2 and doxorubicin 25 mg/m2. Dexrazoxane was administered at 10 times the doxorubicin dose prior to doxorubicin infusion. A cumulative anthracycline exposure up to 750 mg/m2 was allowed. Filgrastim support was provided. DLT was evaluated during the first course and defined as >Grade (gr) 1 cardiac, >gr 1 neuro, gr 4 hematologic lasting > 7days, all other >gr 2 excluding gr 3 infection and any toxicity delaying planned therapy > 14 days. Responding patients were treated for a maximum of 8 courses.

Results: Seventeen patients were enrolled and 16 were evaluable for toxicity on 3 dose levels. Dose level 1 was the determined MTD. Gr 2 cardiac DLT was seen in 1 of 6 patients on dose level 1, gr 4 platelets in 2 of 5 patients on dose level 2 and 1 each of gr 2 cardiac and gr 4 platelets in 5 patients on dose level 3. Cardiac DLT was noted in patients with prior exposure to both anthracyclines and chest radiation. Two of 3 patients with platelet DLT had prior stem cell transplant. No significant neurotoxicity was seen. Oxaliplatin PK is being evaluated. Objective (?partial) responses were noted in 3 neuroblastomas and 1 each of osteosarcoma, mixed germ cell tumor, neurofibrosarcoma, thymic neuroendocrine carcinoma and nasopharyngeal carcinoma. Four patients completed all 8 courses of protocol therapy. Conclusions: Oxaliplatin 105 mg/m2 on day 1 combined with doxorubicin 20 mg/m2 days 1-3 was the MTD. Dexrazoxane administration may have contributed to hematologic toxicity. Significant anti-tumor activity was noted.

 

 

http://abstract.asco.org/AbstView_74_49319.html

 

Audio Lecture By Dr Deepak Edward on Ocular Inflammation

E-mail Print PDF

Ocular Inflammation

 

By Dr. Deepak P. Edward

 

Resource Type: Lecture
Description: The lecture describes in detail the inflammatory process, the cells involved and several types of inflammations affecting the eye.
Author Institution: NEOUCOM, Akron OH.
Content Last Updated: 2010
Educational Objectives: Participants will be able to identify the different cells involved in inflammatory process, explain the functions and processes of ocular inflammation and identify different types of inflammatory processes that affect the eye.
Intended Learner Audience: Ophthalmology residents.

*We will soon add a quiz for this lecture

To listen to the lecture and view slide access this link

http://icopedia.ophthalmologyblogs.org/2010/01/29/ocular-inflammation/

 

Mr Jino Joys Update om the Autumn Muse 2010

E-mail Print PDF

Hello..

I hope you are aware of our attempt to bring back 'Autumn Muse' this year in a grand style. We have drawn a plan for a sports and cultural extravaganza of four days - August 11,12,13,14. (Just a week after the Alumni Reunion). The cause for which Muse would be held this year is 'Unit of Hope'. We are also considering to help 'Child for Life' - Fund for pediatric patients at SJMC. As for the Muse Rock - the top Indian Bands like Parikrama, Mother Jane, Junkyard Groove, Avial etc are being  considered. 'Parikrama' is almost finalized. We are also planning to have a Bollywood singer who would perform on the penultimate day of our fest. Discussions regarding this are progressing. We are putting our Best effort to make this Muse memorable and probably the biggest of all !



But I am afraid to say that we are facing a little problem. Sponsors whom we are approaching are little reluctant in giving enough sums to do the fest. The main reason being the 3 year gap between the last muse and this along with the current economic situation. 

Earlier when we had approached the management for permission to conduct MUSE 2010,  We had agreed not to have any VDs (Voluntary Donations) for Muse. (In Vds the students especially the junior most batch would go house- to house asking for money). This was a main source of income for the muses held before. This gave the organizers then a lot of liquid cash for all the day to day work for Muse.
The total budget for the current  Muse comes up to about 30 lakhs !
 

Video Of Dr Jayasimha Murthy discussing his new test which is less invasive to diagnose Sleep Apnea

E-mail Print PDF

Dr Jayasimha Murthy  assistant professor of medicine from the Division of Pulmonary Critical Care Sleep Medicine at UTHSC at Houston along with computer scientist discovers a new test less invasive, more comfortable way to diagnose this serious condition

To view the news breifing view this link

http://www.google.com/imgres?imgurl=http://www.nsf.gov/news/mmg/media/images/sleep_apnea2_r.jpg&imgrefurl=http://www.nsf.gov/news/news_summ.jsp%3Fcntn_id%3D115876&usg=__pSOkARRyrvv61glK7BzvCZgphog=&h=107&w=124&sz=5&hl=en&start=6&um=1&itbs=1&tbnid=nGOYLM83ngdUfM:&tbnh=78&tbnw=90&prev=/images%3Fq%3Ddr%2Bjayasimha%2Bmurthy%26um%3D1%26hl%3Den%26sa%3DN%26tbs%3Disch:1

A computer scientist from the University of Houston and a doctor of sleep medicine at the University of Texas Health Science Center at Houston have teamed up to create a new, less invasive method of diagnosing sleep apnea. Their findings appear in the November issue of the journal Sleep.

Sleep apnea is serious disorder that causes a person to momentarily stop breathing while they sleep. These pauses in breathing can occur many times an hour, and can cause low oxygen levels in the blood and chronic sleepiness, which in turn can lead to deadly accidents. Sleep apnea has also been associated with a range of serious health problems including depression, heart disease and stroke.

Approximately 24 percent of men and 9 percent of women experience sleep apnea, but getting a diagnosis involves a procedure called polysomnography, also known as a sleep study. "It's not as simple as paying a visit to the doctor in the morning for an hour and walking away with a prescription," said Ioannis Pavlidis, Eckhard-Pfeiffer Professor of Computer Science at the University of Houston, and co-investigator of the study. "You have to undergo overnight monitoring in a sleep lab. The subject is wired and sleeps there. Sometimes, the subject has to spend more than one night."

Adding to the difficulty in getting a sleep apnea diagnosis is the invasive nature of current testing methods. "During a sleep study a subject has an average of more than 20 sensors attached to the head and body. It's a very complex procedure where many physiological parameters are simultaneously monitored to help in the diagnosis of sleep disorders. However, these sensors can disturb sleep and contribute to the patient's anxiety," said Jayasimha N. Murthy, assistant professor of medicine from the Division of Pulmonary Critical Care Sleep Medicine at UTHSC at Houston and study co-investigator.

The new diagnostic procedure developed by Pavlidis, Murthy and their collaborators uses a thermal infrared camera to monitor breathing waveforms and airflow as a patient breathes in and out of his or her nose. The measurements are processed using computational algorithms and produce results that have proved to be as accurate as traditional polysomnography. The new method also provides doctors with more information about the patient's breathing.

"In contrast to the traditional one-dimensional methods, this new method is an imaging one and thus, multi-dimensional," said Pavlidis. "We now can see how airflow is distributed locally throughout the extent of the nostril. We get not a single, but multiple values for each nostril at every point in time and this makes a lot of difference when it comes to appreciating subtle pathology."

The researchers believe that this new technology could change the way sleep apnea is diagnosed, potentially helping millions of Americans sleep better and possibly live longer.

http://www.google.com/imgres?imgurl=http://www.nsf.gov/news/mmg/media/images/sleep_apnea2_r.jpg&imgrefurl=http://www.nsf.gov/news/news_summ.jsp%3Fcntn_id%3D115876&usg=__pSOkARRyrvv61glK7BzvCZgphog=&h=107&w=124&sz=5&hl=en&start=6&um=1&itbs=1&tbnid=nGOYLM83ngdUfM:&tbnh=78&tbnw=90&prev=/images%3Fq%3Ddr%2Bjayasimha%2Bmurthy%26um%3D1%26hl%3Den%26sa%3DN%26tbs%3Disch:1

 


Page 4 of 29